Cooley advised CrossBridge Bio, a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs), on its agreement to be acquired by Eli Lilly and Company (“Lilly”) for up to $300 million in cash, inclusive of an upfront payment and a subsequent payment upon achieving a specified development milestone.
CrossBridge Bio Acquired by Eli Lilly and Co. for up to $300 Million